CRISPR Therapeutics today announced interim results from its ongoing Phase 1/2 clinical trial of CTX112, an allogeneic CAR-T cell therapy for systemic lupus erythematosus (SLE) and other severe autoimmune disorders.
Presented at a major medical conference, the results showed that a significant percentage of patients treated with CTX112 achieved a meaningful reduction in disease activity. The therapy’s safety profile was consistent with previous observations.
The company said the early results support the potential of its gene-editing platform to offer new treatment options for patients with limited choices. Analysts described the update as a step toward expanding CRISPR Therapeutics’ pipeline beyond oncology and genetic disorders.
The market reaction was positive in pre-market trading as investors assessed the potential to enter the multi-billion-dollar autoimmune treatment market.